Alembic Pharma Q1 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
No
0 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- US business expected to grow 10%-15% for the full year, supported by volume gains and product launches (4 launched in Q1, 10-15 planned for rest of the year).
- Rest of World (RoW) generics saw 21% growth in Q1; expected to grow 10%-15% for the full year.
- India business aims to return to double-digit growth within months; currently working on improving execution and aligning with market norms.
- New manufacturing facilities ramp-up and cost optimization initiatives expected to improve operating leverage and margins.
- API business has been muted but showing potential for recovery after pricing pressures stabilize.
- Overall 10% year-on-year revenue growth achieved in Q1, with broad-based growth despite pricing pressures.
See what Alembic Pharma management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No specific mention of any new fundraising through debt or equity during the call.
- Gross debt as of June 30, 2025, stands at Rs. 1,185 crores and net debt at Rs. 967 crores, broadly similar to March levels.
- Future debt movement is expected to depend on working capital needs and business growth trajectory.
- Management is cautious and will reassess debt reduction or increases in upcoming quarters based on US market dynamics.
- No indication of equity fundraising discussed in the call.
See what Alembic Pharma management said on order book — free account, 30 seconds.
Capex plans
No- Most new capacity augmentation projects have been completed.
- Current CAPEX is primarily directed towards maintenance, replacement, and debottlenecking wherever necessary.
- There is very little CAPEX planned for major expansion or upgrades at this time.
- The company guided for a CAPEX of about Rs. 400 crores for the year, which will be capitalized incrementally over the quarters.
- Depreciation expense increased due to commissioning of a new indoor manufacturing facility for the blended business.
- Future CAPEX impact on depreciation will be reflected as and when assets are capitalized.
- No large capital allocation planned for setting up manufacturing in the US due to pricing pressure and uncertain tariff impacts.
Track Alembic Pharma — get its next earnings analysis in your feed
How does Alembic Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Alembic Pharma rank in Pharmaceuticals & Biotechnology?
Compare Alembic Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY26) on revenue, margins and earnings-call signals.
Continue your research
What Alembic Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.